An open-label 12 month study to evaluate the safety, tolerability and efficacy of OraVescent fentanyl citrate [fentanyl] for the management of breakthrough pain in opioid-tolerant patients with chronic noncancer pain

Trial Profile

An open-label 12 month study to evaluate the safety, tolerability and efficacy of OraVescent fentanyl citrate [fentanyl] for the management of breakthrough pain in opioid-tolerant patients with chronic noncancer pain

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Nov 2007

At a glance

  • Drugs Fentanyl (Primary)
  • Indications Pain
  • Focus Adverse reactions; Registrational
  • Sponsors Cephalon
  • Most Recent Events

    • 13 Nov 2007 Status changed from in progress to completed.
    • 10 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top